Onstituted 8.2562.6 (median 3.76 , IQR [0.96 ?5.8 ], n = 14) (Fig. 1). Next, we estimated the depletion of CD4 T cells by comparing the ratio of CD8+ to CD4+ T cells (i.e. CD82CD3+) in infected and uninfected controls [5,8,10]. To pool data obtained from different donors, we normalized the data by expressing the CD4/ CD8 ratio in infected tissue as a percent of the same ratio in matched uninfected controls [5,8,10]. Infection with C/R viruses and T/F viruses resulted in the significant depletion of tissue CD4 T cells. First, we compared CD4 T cell depletion in donor-matched B1939 mesylate biological activity cervical tissues infected with the T/F HIV-1 NL-1051.TD12.ecto to that infected with a control C/R HIV-1 variant NL-SF162.ecto. There was no statistical difference between the CD4 T cell depletion by these viruses (LY317615 custom synthesis respectively 27.86628.6 and 57.07613.8 , n = 4, p = 0.67). Next, we pooled data for all of the T/F and C/R HIV-1 variants used in the current study. These viruses respectively depleted 42.966.0 (median 35.26 , IQR [27.1 ?1.7 ], n = 19, p,0.0001) and 20.968.9 (median 27.32 IQR [3.01 ?5.65 ], n = 14, p = 0.025) of CD4 T cells. Thus, the depletion of CD4 T cells in tissues infected with these two types of HIV-1 variants was not different (p = 0.08) (Fig. 2). CD4 T cell depletion positively correlated with the proportion of infected cells in the remaining CD4 T cells as measured by flow cytometry (Spearman r = 0.5642, p,0.0001, n = 34). In tissues treated with 3TC, HIV-1 inoculation did not result in cell depletion: the fraction of CD4 T cells in such tissues was not statistically different from that in donor-matched uninfected tissues (n = 32, p.0.5).Finally, we compared activation status of CD4 T cells (Fig. 3) as evaluated by the expression of the following activation markers: CD25, CD38, CD69, CD95, and HLA-DR. In uninfected tissues these markers were respectively expressed by 11.2161.96 , 29.1164.3 , 77.3565.08 , 73.1268.81 , and 7.0761.29 of CD4 T cells (n = 24). As with the data regarding HIV-1 infection and CD4 T cell depletion we first compared activation of T cells by their expression of CD25, CD38, and HLA-DR in donor-matched tissues infected with a T/F HIV-1 construct, NL-1051.TD12.ecto and a control C/R HIV-1 variant, NL-SF162.ecto. We found that CD25, CD38, and HLA-DR expression by p24+ CD4 T cells did not differ in tissues infected by these respective viruses. CD25 was expressed on respectively 20610 and 2269.7 (n = 3, p = 0.72) of cells infected by the HIV-1 variant NL-1051.TD12.ecto and the HIV-1 variant NL-SF162.ecto. For CD38, these fractions constituted respectively 33.4610.7 and 40.4610.3 (n = 3, p = 0.72), while for HLA-DR, these fractions were 6.0362.5 and 8.7563.8 (n = 3, p = 0.38), respectively. These results were confirmed when we analyzed the expression of activation markers in the group of tissues infected with T/F 15857111 HIV-1 variants as compared to the group infected with C/R HIV-1 variants. In tissues infected with C/R HIV-1 variants, CD25, CD38, CD69, CD95, and HLA-DR were respectively expressed by 15.0362.67 , 24.2764.25 , 78.1762.77 , 80.1569.14 , and 7.6161.58 of the p24+ CD4 T cells. In tissues infected with T/F viruses, these markers were expressed by 17.4463.57 , 28.3965.26 , 75.0464.83 , 80.16612.12 , and 5.861.58 of p24+ CD4 T cells. In order to distinguish the effects of viral infection from the normal variation of marker expression between donor tissues, for each matched tissue, we calculated the level of expre.Onstituted 8.2562.6 (median 3.76 , IQR [0.96 ?5.8 ], n = 14) (Fig. 1). Next, we estimated the depletion of CD4 T cells by comparing the ratio of CD8+ to CD4+ T cells (i.e. CD82CD3+) in infected and uninfected controls [5,8,10]. To pool data obtained from different donors, we normalized the data by expressing the CD4/ CD8 ratio in infected tissue as a percent of the same ratio in matched uninfected controls [5,8,10]. Infection with C/R viruses and T/F viruses resulted in the significant depletion of tissue CD4 T cells. First, we compared CD4 T cell depletion in donor-matched cervical tissues infected with the T/F HIV-1 NL-1051.TD12.ecto to that infected with a control C/R HIV-1 variant NL-SF162.ecto. There was no statistical difference between the CD4 T cell depletion by these viruses (respectively 27.86628.6 and 57.07613.8 , n = 4, p = 0.67). Next, we pooled data for all of the T/F and C/R HIV-1 variants used in the current study. These viruses respectively depleted 42.966.0 (median 35.26 , IQR [27.1 ?1.7 ], n = 19, p,0.0001) and 20.968.9 (median 27.32 IQR [3.01 ?5.65 ], n = 14, p = 0.025) of CD4 T cells. Thus, the depletion of CD4 T cells in tissues infected with these two types of HIV-1 variants was not different (p = 0.08) (Fig. 2). CD4 T cell depletion positively correlated with the proportion of infected cells in the remaining CD4 T cells as measured by flow cytometry (Spearman r = 0.5642, p,0.0001, n = 34). In tissues treated with 3TC, HIV-1 inoculation did not result in cell depletion: the fraction of CD4 T cells in such tissues was not statistically different from that in donor-matched uninfected tissues (n = 32, p.0.5).Finally, we compared activation status of CD4 T cells (Fig. 3) as evaluated by the expression of the following activation markers: CD25, CD38, CD69, CD95, and HLA-DR. In uninfected tissues these markers were respectively expressed by 11.2161.96 , 29.1164.3 , 77.3565.08 , 73.1268.81 , and 7.0761.29 of CD4 T cells (n = 24). As with the data regarding HIV-1 infection and CD4 T cell depletion we first compared activation of T cells by their expression of CD25, CD38, and HLA-DR in donor-matched tissues infected with a T/F HIV-1 construct, NL-1051.TD12.ecto and a control C/R HIV-1 variant, NL-SF162.ecto. We found that CD25, CD38, and HLA-DR expression by p24+ CD4 T cells did not differ in tissues infected by these respective viruses. CD25 was expressed on respectively 20610 and 2269.7 (n = 3, p = 0.72) of cells infected by the HIV-1 variant NL-1051.TD12.ecto and the HIV-1 variant NL-SF162.ecto. For CD38, these fractions constituted respectively 33.4610.7 and 40.4610.3 (n = 3, p = 0.72), while for HLA-DR, these fractions were 6.0362.5 and 8.7563.8 (n = 3, p = 0.38), respectively. These results were confirmed when we analyzed the expression of activation markers in the group of tissues infected with T/F 15857111 HIV-1 variants as compared to the group infected with C/R HIV-1 variants. In tissues infected with C/R HIV-1 variants, CD25, CD38, CD69, CD95, and HLA-DR were respectively expressed by 15.0362.67 , 24.2764.25 , 78.1762.77 , 80.1569.14 , and 7.6161.58 of the p24+ CD4 T cells. In tissues infected with T/F viruses, these markers were expressed by 17.4463.57 , 28.3965.26 , 75.0464.83 , 80.16612.12 , and 5.861.58 of p24+ CD4 T cells. In order to distinguish the effects of viral infection from the normal variation of marker expression between donor tissues, for each matched tissue, we calculated the level of expre.